Tivicay is the brand name for dolutegravir, an integrase strand transfer inhibitor (INSTI) medication used in the treatment of HIV-1 infection [1]. It is typically used in combination with other antiretroviral agents [2].
How does Tivicay work to treat HIV?
Tivicay works by blocking the action of an enzyme called integrase, which HIV uses to integrate its genetic material into the host cell's DNA [1]. By inhibiting integrase, Tivicay prevents the virus from replicating [1].
What other HIV medications is Tivicay often combined with?
Tivicay is commonly used in combination regimens. For instance, it is available as a fixed-dose combination pill with abacavir and lamivudine (Triumeq) [3]. It can also be combined with other antiretroviral drugs such as emtricitabine and tenofovir disoproxil fumarate [2].
When does Tivicay's patent protection expire?
The patent expiration dates for Tivicay can vary by country and specific patent. DrugPatentWatch.com provides detailed information on these patent statuses [4]. For example, some patents related to dolutegravir and its formulations may expire in the coming years, opening the door for generic competition [4].
Are there generic versions of Tivicay available or expected?
As patents expire, generic versions of dolutegravir are expected to become available. The timeline for generic entry depends on the specific patent landscape and any regulatory approvals [4].
What are the potential side effects of Tivicay?
Common side effects associated with Tivicay can include insomnia, headache, diarrhea, nausea, and fatigue [1]. Less common but serious side effects may include hypersensitivity reactions and liver problems [1].
How does Tivicay compare to other HIV integrase inhibitors?
Tivicay is part of a class of drugs called integrase strand transfer inhibitors. Other drugs in this class include raltegravir and elvitegravir. These medications share a similar mechanism of action but may differ in their efficacy, side effect profiles, and drug-drug interaction potential [5].
What is the typical dosage and administration for Tivicay?
The standard dosage for Tivicay in treatment-naïve adults is 50 mg taken once daily [1]. For individuals with certain resistance mutations, a 50 mg twice-daily dosage may be prescribed [1]. It can be taken with or without food [1].
Are there any significant drug interactions with Tivicay?
Tivicay can interact with certain medications. For instance, it may interact with antacids containing polyvalent cations, which can reduce its absorption [1]. It is important for patients to inform their healthcare provider about all medications they are taking [1].
What clinical trials have been conducted for Tivicay?
Multiple clinical trials have demonstrated Tivicay's efficacy in treating HIV-1 infection, both in treatment-naïve individuals and those who have previously received treatment [2]. Studies have shown high rates of viral suppression and increases in CD4 cell counts [2].
Where can I find more detailed patent information for Tivicay?
For comprehensive details on Tivicay's patent status, including expiration dates and any ongoing litigation, DrugPatentWatch.com is a valuable resource [4].
---
1. Tivicay [prescribing information]. ViiV Healthcare; 2023.
2. Cahn, P., et al. (2014). Dolutegravir monotherapy, after⩽24 weeks of standard combination therapy, in HIV-1-infected adults: the VIKING-3 randomisation trial. The Lancet, 384(9937), 71-77.
3. Triumeq [prescribing information]. ViiV Healthcare; 2023.
4. DrugPatentWatch. (n.d.). Dolutegravir (Tivicay) Patents. Retrieved from https://drugpatentwatch.com/drug/dolutegravir
5. Sax, P. E., et al. (2015). Integrase strand transfer inhibitors in the management of human immunodeficiency virus type 1 infection: a review. Clinical Infectious Diseases, 60(suppl_1), S3-S9.